GALT Key Stats
- Nasdaq stocks posting largest percentage increases Dec 6
- Galectin Therapeutics (GALT) in Focus: Stock Moves Up 13.2% Dec 4
- Galectin Therapeutics (GALT) in Focus: Stock Moves Up 13.2% - Tale of the Tape Zacks Dec 4
- 4 Stocks Under $10 Moving Higher The Street Dec 4
- MLV & Co. Starts Galectin Therapeutics (GALT) at Buy Street Insider Dec 3
- Coverage initiated on Galectin Therapeutics by MLV & Co Dec 3
- Galectin Therapeutics: 7 Different Insiders Have Purchased Shares This Month Dec 1
- GALECTIN THERAPEUTICS INC Financials Nov 19
- Oversold Conditions For Galectin Therapeutics (GALT) Nov 18
- 4 Healthcare Stock Stories Ready for an Investment Checkup Wall St. Cheat Sheet Nov 12
GALT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Galectin Therapeutics is up 359.4% over the last year vs S&P 500 Total Return up 29.87%, Lannett Company up 520.1%, and Sucampo Pharmaceuticals up 53.02%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for GALT
Pro Strategies Featuring GALT
Did Galectin Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Galectin Therapeutics, Inc. offers drug research & development to create new therapies for fibrotic disease & cancer. It has two compounds in development; one to be used in treatment of liver fibrosis & fatty liver disease & the other in cancer therapy.